Empagliflozin/Linagliptin

DRUG2 trials

Sponsors

Boehringer Ingelheim, JW Pharmaceutical

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes Mellitus (T2DM)

Phase 4

Glycemic Variability of Combination Therapies in T2DM

RecruitingNCT07442006

JW PharmaceuticalType 2 Diabetes Mellitus (T2DM)

Start: 2025-10-29End: 2027-03-31Target: 178Updated: 2026-03-02

Unknown Phase

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

CompletedNCT05130463

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2022-03-22End: 2024-07-08Updated: 2025-08-27